Quintrio
Home

PHARMACEUTICAL PREPARATIONS

ARS Pharmaceuticals, Inc. Common Stock

SPRY

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Last trade $3.70
Day change +$0.11 (+3.06%)
Day range $3.51 – $3.78
Volume 721,975
Market cap $361M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$360.9M
Price / earnings
—
Price / book
-30.19×
Price / sales
2.95×
EV / sales
4.36×
EV / EBITDA
-2.72×

Profitability

Earnings per share
-$1.99
Return on assets
-79.39%
Return on equity
1,669.94%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-16.48×
Current ratio
3.25×
Quick ratio
3.07×
Cash ratio
0.39×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$183.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SPRY, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$37.71M$33.66M$22.68M$28.09M$32.5M$15.72M$7.97M$86.58M
Cost of revenue$10.1M$12.85M$6.29M$6.15M$8.19M$4.98M$1.09M$865K
Gross profit$27.61M$20.81M$16.4M$21.93M$24.31M$10.73M$6.88M$85.72M
Selling, general and administrative$43.52M$77.58M$72.2M$59.96M$74.75M$54.31M$41.1M$35.49M
Research and development$18.26M$4.7M$4.34M$3.44M$2.75M$4.04M$2.95M$3.03M
Total operating expenses$61.78M$82.28M$76.54M$63.4M$77.5M$58.35M$44.06M$38.52M
Operating income-$34.17M-$61.47M-$60.15M-$41.47M-$53.19M-$47.61M-$37.18M$47.2M
Interest expense-$2.55M-$2.48M$0$0-$56K$0$0$0
Income before taxes-$35.59M-$62.34M-$60.62M-$41.18M-$51.15M-$44.88M-$33.94M$49.93M
Income taxes$0$0$0-$80K$0$0$0$288K
Net income-$35.59M-$62.34M-$60.62M-$41.1M-$51.15M-$44.88M-$33.94M$49.64M
Net income attributable to common shareholders-$35.59M-$62.34M-$60.62M-$41.1M-$51.15M-$44.88M-$33.94M$49.64M
EBITDA-$33.76M-$61.05M-$59.75M-$41.05M-$52.8M-$47.34M-$36.9M$47.23M
Basic earnings per share-$0.36-$0.63-$0.61-$0.41-$0.52-$0.46-$0.35$0.51
Diluted earnings per share-$0.36-$0.63-$0.61-$0.41-$0.52-$0.46-$0.35$0.42

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates

ARS Pharmaceuticals reported a Q3 loss of $0.36 per share, missing consensus estimates of $0.34 loss, and posted revenues of $37.71 million, falling 11.66% short of expectations. The stock has declined 73.8% year-to-date and received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.

GlobeNewswire Inc.

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

GlobeNewswire Inc.

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.

GlobeNewswire Inc.

ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.